’A third’ of Levothyrox patients have dropped the productFriday’s L’Humanité (brief p19) and radio station France Info reported that a third of patients who used to take Merck KGaA’s Levothyrox - about 500,000 people - have stopped treatment because of the fear of side effects, according to figures published by the health minister.
Biom’Up invests 15 million euros, creates 200 jobsSurgical haemostasis company Biom’Up has decided to invest 15 million euros in a new plant, wrote Les Echos (p28) on Thursday.
Has Sanofi been too hasty with its dengue vaccine?Wednesday’s Le Monde (Science and Medicine supplement, p4) published an article on the uproar Sanofi is facing with the failure of its dengue vaccine, after the vaccination campaign was stopped in the Philippines amid safety issues, leading local authorities to sue the company.
Sanofi signs R&D deal with Evotec in infectious diseasesFriday’s Les Echos (p19) and Le Figaro (brief p21) report on the R&D deal signed by Sanofi with Evotec to develop new antimicrobials (APMHE 57226).
Healthcare and biotech main contributors to patent request boom in EuropeThursday’s Les Echos (p19) and La Croix (p10) reported that the healthcare and biotech sectors are the main contributors to patent requests in Europe, which reached record levels last year.
MS treatment Zinbryta pulled from European marketThursday’s Le Figaro (brief p11) reported briefly on EMA’s decision to withdraw AbbVie/Biogen’s multiple sclerosis treatment Zinbryta (Biogen) from the market, because of risks of severe brain inflammation (APMHE 57192).
Change at the helm of GSK FranceThursday’s Les Echos (brief p35) and Le Figaro (brief p24) reported that Josephine Yang Comiskey has been appointed president of GlaxoSmithKline France. (APMHE 57202)
TRY APM HEALTH EUROPE AND GET ACCESS TO THE FULL CONTENT
Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations
Events coverage with a unique focus on Market Access & sustainability of healthcare systems
6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris
Ask for a Free trial and get access to our last stories
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
an initial 10 day temporary access of APM Health Europe.